Abstracts tagged "Diacerein"

Abstract Number: 1318 • 2019 ACR/ARP Annual Meeting
In an International, Multicentre, Double-blind, Randomised Study in Knee Osteoarthritis Patients, Diacerein Was Found as Effective as Celecoxib in Reducing Pain and Disease Symptoms
Jean-Pierre Pelletier¹, Jean-Pierre Raynauld ², Patrice Paiement ³, Marc Dorais ⁴ and Johanne Martel-Pelletier ⁵, ¹University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ²Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ³ArthroLab Inc., Montreal, QC, Canada, ⁴StatSciences Inc., Notre-Dame-de-l'Île-Perrot, QC, Canada, ⁵University of Montreal Hospital Research Centre (CRCHUM), Montreal, Canada
Background/Purpose: There was a need to ascertain in a clinical trial the comparative efficacy of diacerein, an IL-1 inhibitor, vis-à-vis celecoxib, a COX-2 inhibitor, in…
Abstract Number: 1033 • 2018 ACR/ARHP Annual Meeting
Comparison of Oral Administration of Diacerein, Intra-Articular Injection of Diacerein Solution, and Intra-Articular Injection of Diacerein-Loaded Nanoparticle in Osteoarthritis Rat Model
Jae Hyun Jung^1,2, Sung Jae Choi^1,3, Gwan Gyu Song^1,2, Sung Eun Kim⁴ and Hak-Jun Kim^5,6, ¹Internal Medicine, Korea University College of Medicine, Seoul, Korea, Republic of (South), ²Internal Medicine, Korea University Guro Hospital, Seoul, Korea, Republic of (South), ³Internal Medicine, Korea University Ansan Hospital, Ansan, Korea, Republic of (South), ⁴Orthopedic Surgery, Korea University Guro Hospitial, Seoul, Korea, Republic of (South), ⁵Orthopedic Surgery, Korea Univertisy College of Medicine, Seoul, Korea, Republic of (South), ⁶Orthopedic Surgery, Korea University Guro Hospital, Seoul, Korea, Republic of (South)
Background/Purpose: Osteoarthritis (OA) treatment is typically administered to control symptoms. Diacerein (DIA) reduces interleukin (IL)-1 receptor on chondrocytes and prevents structural degradation of joint tissue.…
Abstract Number: 1114 • 2017 ACR/ARHP Annual Meeting
Effects of Diacerein Controlled Release Tablets in Serum Uric Acid Reduction in Treating Subjects with Gout
Ying-Chou Chen Sr.¹, Shih-Chueh Chen², Chung-Tei Chou³, Carl Brown⁴, Jing-Yi Lee⁴, Wei-Shu Lu⁵ and Chang Youh Tsai⁶, ¹Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung County, Taiwan, ²Department of Endocrinology, Cheng Ching General Hospital, Taichung, Taiwan, ³Division of Allergy-Immunology-Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ⁴Medical Research, TWi Biotechnology, Inc., Taipei, Taiwan, ⁵TWi Biotechnology, Inc., Taipei, Taiwan, ⁶Division of Allergy- Immunology- Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
Background/Purpose: The goal of gout treatment is to reduce serum uric acid (sUA) concentrations below the urate solubility limit. Diacerein is known as an oral…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].